PubMed Health⌕ Search

PubMed · 15348015

Processing and properties of two different poly (ortho esters).

Abstract

Processing and properties of two structurally different poly (ortho esters) (POE) and their in vitro behavior have been compared. One POE was a copolymer of diketene acetal 3,9-diethylidene-2,4,8,10-tetraoxaspiro[5.5]undecane, trans-cyclohexanedimethanol and polyacetal. The other POE was a copolymer of diketene acetal 3,9-diethylidene-2,4,8,10-tetraoxaspiro[5.5]undecane, trans-cyclohexanedimethanol and trans-cyclohexanedimethanol-dilactide. The polyacetal POE was also used as a matrix incorporating two different model drugs, caffeine and furosemide. Both polymers were ultrasonically molded into slabs. The lactide modified POE was also melt-extruded into rods and self-reinforced using a solid state die-drawing technique. The initial strength values of both ultrasonically molded and extruded samples were close to those of non-oriented poly lactic acids. Self-reinforcing increased the shear strength, bending strength and modulus of the rods from 41.7+/-1.7 MPa to 66.7+/-2.3 MPa, from 78.5+/-22.8 MPa to 183+/-23 MPa and from 2.5+/-0.3 GPa to 4.4+/-0.3 GPa, respectively. In vitro hydrolysis of samples was studied either in phosphate buffer saline (PBS) or in simulated body fluid (SBF) at 37 degrees C. Samples degraded faster in unchanged PBS than in PBS changed weekly. The total in vitro strength retention time was relatively short varying from 14 days to 42 days depending on the processing method and polymer type. Samples retained their wet weight at initial level for a longer time but dry weight started to decrease already after the first in vitro week. Polymers or degradation products crystallized in SBF but remained amorphous when hydrolyzed in PBS. Some of the devices showed evidence of surface erosion, and the processing method affected the erosion. The storage time of these polymers was found to be limited. However, both polymers were found to be of interest in bone fixation and tissue engineering.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Kellomäki, J Heller, P Törmälä. 2000. Processing and properties of two different poly (ortho esters).. https://doi.org/10.1023/a%3A1008977806693

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗